420P A single-arm, multicenter, phase II study of anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ALTER-C002)

Unresectable Metastatic Colorectal Cancer

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Multicenter Phase ◽

First Line Treatment ◽

469P Efficacy and safety of anlotinib combined with CAPEOX in first-line treatment of patients with RAS and BRAF wild-type unresectable metastatic colorectal cancer - A single-arm, multi-center, phase II study (ALTER-C-002 trial)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.580 ◽

2020 ◽

Vol 31 ◽

pp. S440

Author(s):

K. Ding ◽

Y. Liu ◽

J. Chen ◽

J. Ying ◽

Q. Xu ◽

...

Keyword(s):

Colorectal Cancer ◽

Unresectable Metastatic Colorectal Cancer

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

Efficacy And Safety ◽

Wild Type ◽

First Line ◽

First Line Treatment ◽

A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-003-0601-4 ◽

2003 ◽

Vol 52 (4) ◽

pp. 339-345 ◽

Cited By ~ 3

Author(s):

Juan José Reina ◽

Jorge Aparicio ◽

Javier Salvador ◽

José María Puerto Pica ◽

Antonio Rueda ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽

FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study

Clinical Colorectal Cancer ◽

10.1016/j.clcc.2015.02.006 ◽

2015 ◽

Vol 14 (3) ◽

pp. 162-169 ◽

Cited By ~ 6

Author(s):

Nicola Personeni ◽

Lorenza Rimassa ◽

Claudio Verusio ◽

Sandro Barni ◽

Luca Rubino ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Phosphatase And Tensin Homolog ◽

Tensin Homolog ◽

1322 Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in elderly patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10

European Journal of Cancer ◽

10.1016/s0959-8049(16)30565-2 ◽

2015 ◽

Vol 51 ◽

pp. S194-S195 ◽

Cited By ~ 1

Author(s):

D. Kienle ◽

R. Winterhalder ◽

D. Koeberle ◽

D. Horber ◽

M. Kueng ◽

...

Keyword(s):

Colorectal Cancer ◽

Elderly Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Multicenter Phase ◽

A Phase II Study of Cetuximab Plus Irinotecan/S-1 as First-Line Treatment in KRAS Wild-Type Metastatic Colorectal Cancer

Annals of Oncology ◽

10.1093/annonc/mdt459.47 ◽

2013 ◽

Vol 24 ◽

pp. ix41

Author(s):

T. Masuishi ◽

Y. Sakai ◽

T. Matsui ◽

R. Nakamura ◽

S. Anzai ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer

British Journal of Cancer ◽

10.1038/sj.bjc.6605075 ◽

2009 ◽

Vol 100 (11) ◽

pp. 1720-1724 ◽

Cited By ~ 22

Author(s):

E Vasile ◽

G Masi ◽

L Fornaro ◽

S Cupini ◽

F Loupakis ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽

A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer

Investigational New Drugs ◽

10.1007/s10637-011-9779-1 ◽

2011 ◽

Vol 30 (5) ◽

pp. 2026-2031 ◽

Cited By ~ 7

Author(s):

Natsuko T. Okita ◽

Taito Esaki ◽

Eishi Baba ◽

Daisuke Sakai ◽

Shinya Tokunaga ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽

Stop And Go ◽

Modified Folfox6 ◽

Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)

Oncology Letters ◽

10.3892/ol.2016.5505 ◽

2016 ◽

Vol 13 (2) ◽

pp. 747-753 ◽

Cited By ~ 3

Author(s):

Masanori Kotake ◽

Toru Aoyama ◽

Yoshinori Munemoto ◽

Kenji Doden ◽

Masato Kataoka ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽

FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-013-2292-9 ◽

2013 ◽

Vol 72 (5) ◽

pp. 1097-1102 ◽

Cited By ~ 7

Author(s):

Mitsugu Kochi ◽

Yuji Akiyama ◽

Tatsuya Aoki ◽

Ken Hagiwara ◽

Takao Takahashi ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Japanese Patients ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽

Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10

Journal of Geriatric Oncology ◽

10.1016/j.jgo.2018.11.011 ◽

2019 ◽

Vol 10 (2) ◽

pp. 304-310 ◽

Cited By ~ 7

Author(s):

Dirk L. Kienle ◽

Daniel Dietrich ◽

Karin Ribi ◽

Andreas Wicki ◽

Luca Quagliata ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Older Patients ◽

Phase Ii Trial ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Multicenter Phase ◽